These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22292133)

  • 21. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
    Hu J; Yu H; Kornev AP; Zhao J; Filbert EL; Taylor SS; Shaw AS
    Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6067-72. PubMed ID: 21441104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.
    Richman J; Martin-Liberal J; Diem S; Larkin J
    Expert Opin Pharmacother; 2015 Jun; 16(9):1285-97. PubMed ID: 26001180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
    Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
    Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRAF R391W is a melanoma driver oncogene.
    Atefi M; Titz B; Tsoi J; Avramis E; Le A; Ng C; Lomova A; Lassen A; Friedman M; Chmielowski B; Ribas A; Graeber TG
    Sci Rep; 2016 Jun; 6():27454. PubMed ID: 27273450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.
    Conrad WH; Swift RD; Biechele TL; Kulikauskas RM; Moon RT; Chien AJ
    Cell Cycle; 2012 Oct; 11(20):3724-30. PubMed ID: 22895053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.
    Wada M; Horinaka M; Yamazaki T; Katoh N; Sakai T
    PLoS One; 2014; 9(11):e113217. PubMed ID: 25422890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.
    Xu J; Pfarr N; Endris V; Mai EK; Md Hanafiah NH; Lehners N; Penzel R; Weichert W; Ho AD; Schirmacher P; Goldschmidt H; Andrulis M; Raab MS
    Oncogenesis; 2017 May; 6(5):e337. PubMed ID: 28504689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical
    Dumaz N; Jouenne F; Delyon J; Mourah S; Bensussan A; Lebbé C
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31398831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
    Hong SP; Ahn SK
    Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
    Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
    Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
    Ming Z; Lim SY; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.
    Houben R; Becker JC; Kappel A; Terheyden P; Bröcker EB; Goetz R; Rapp UR
    J Carcinog; 2004; 3():6. PubMed ID: 15046639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
    Bhargava A; Anant M; Mack H; ;
    Elife; 2016 Feb; 5():. PubMed ID: 26885666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The plasma membrane Ca
    Hegedũs L; Garay T; Molnár E; Varga K; Bilecz Á; Török S; Padányi R; Pászty K; Wolf M; Grusch M; Kállay E; Döme B; Berger W; Hegedũs B; Enyedi A
    Int J Cancer; 2017 Jun; 140(12):2758-2770. PubMed ID: 27813079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absence of mutations in the coding sequence of the potential tumor suppressor 3pK in metastatic melanoma.
    Houben R; Becker JC; Rapp UR
    J Carcinog; 2005 Dec; 4():23. PubMed ID: 16367997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
    Henry JR; Kaufman MD; Peng SB; Ahn YM; Caldwell TM; Vogeti L; Telikepalli H; Lu WP; Hood MM; Rutkoski TJ; Smith BD; Vogeti S; Miller D; Wise SC; Chun L; Zhang X; Zhang Y; Kays L; Hipskind PA; Wrobleski AD; Lobb KL; Clay JM; Cohen JD; Walgren JL; McCann D; Patel P; Clawson DK; Guo S; Manglicmot D; Groshong C; Logan C; Starling JJ; Flynn DL
    J Med Chem; 2015 May; 58(10):4165-79. PubMed ID: 25965804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF somatic mutations in malignant melanoma and melanocytic naevi.
    Thomas NE
    Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF.
    Yuan J; Ng WH; Yap J; Chia B; Huang X; Wang M; Hu J
    J Biol Chem; 2018 Sep; 293(37):14276-14284. PubMed ID: 30030377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.